Stocktoria
Anbio Biotechnology NNNN
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2025-02-19
Chart by TradingView
4/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $8.6M | $8.2M | $6.7M |
| Gross profit | $7.5M | $5.9M | $3.4M |
| Operating income | $5.8M | $2.0M | $2.0M |
| Net income | $6.4M | $2.4M | $2.3M |
| Operating cash flow | -$6.7M | $2.1M | $898,367 |
| Total assets | $30.2M | $18.9M | $15.8M |
| Total liabilities | $87,836 | $1.7M | $993,060 |
| Shareholders' equity | $30.2M | $17.2M | $14.8M |
| Ratios | |||
| Gross margin | 87.2% | 71.9% | 50.1% |
| Operating margin | 66.7% | 24.4% | 29.2% |
| Net margin | 74.1% | 29.0% | 33.6% |
| Return on assets | 21.2% | 12.5% | 14.3% |
| Return on equity | 21.2% | 13.8% | 15.2% |
| Current ratio | 344.31 | 10.71 | 15.86 |
| Revenue growth | 5.6% | 21.9% | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001982708 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.